Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talnetant vs Placebo vs Risperidone in Schizophrenia
NCT00049946Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2002
- Primary completion
- Apr 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of talnetant in schizophrenia (3 arms), sponsored by GSK. Primary endpoint: Positive and Negative Syndrome Scale Total Score. Started Oct 2002; status: completed.
02
Drugs
talnetant
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00049946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049946.